The effect of antidiabetic treatment on the bone of patients with type 2 diabetes

Česká verzia

Authors: David Karásek
Authors place of work: III. interní klinika – nefrologická, revmatologická a endokrinologická LF UP a FN Olomouc
Published in the journal: Vnitř Lék 2016; 62(7-8): 582-587
Category: Reviews

Summary

Despite a normal or higher bone mass, type 2 diabetes is associated with a higher risk of osteoporotic fractures. Besides a higher falls frequency the lower quality of diabetics bone plays the crucial role in this case. One of the factors affecting their fracture risk is a choice of antidiabetic treatment. So far, professional societies have warned before the thiazolidinediones use only, but gliflozines can be harmful for bone too. Metformin, sulfonylureas, GLP-1 agonists and DPP-4 inhibitors belong to the drugs without a negative effect on the fracture risk. The increased frequency of bone fractures in diabetics treated with insulin lies more in the fact that these patients suffer from diabetes longer, have more diabetic complications and are at a higher risk of hypoglycemia, which is associated with a higher frequency of falls. In individuals with a high fracture risk antidiabetic drugs without a negative effect on bones should be recommended.

Key words:
DPP–4 inhibitors – gliflozines – GLP–1 agonists – insulin – metformin – osteoporosis – sulfonylureas – thiazolidinediones – type 2 diabetes mellitus

Zdroje

1. Činnost oboru diabetologie, péče o diabetiky v roce 2013. UZIS: Praha 2015; 2. Dostupné z WWW: <http://www.uzis.cz/rychle-informace/cinnost-oboru-diabetologie-pece-diabetiky-roce-2013>.

2. Palička V, Blahoš J, Býma S. [Centrum doporučených postupů pro praktické lékaře]. Osteoporóza – doporučený diagnostický a léčebný postup pro všeobecné praktické lékaře 2011. Společnost všeobecného lékařství ČLS JEP: Praha 2011. ISBN 978–80–86998–44–2.

3. Palička V, Lesná J, Pavlíková L. Změny kostního metabolizmu u diabetiků. Vnitř Lék 2014; 60(9): 742–745.

4. FRAX® WHO Fracture Risk AssessmentTool. Calculation Tool. Dostupné z WWW: <http://www.shef.ac.uk/FRAX/tool.jsp?locationValue=9>.

5. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes – a meta-analysis. Osteoporos Int 2007; 18(4): 427–444.

6. Janghorbani M, Van Dam RM, Willett WC et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007; 166(5): 495–505.

7. Reid IR. Relationships among body mass, its components, and bone. Bone 2002; 31: 547–555.

8. Kawai M, de Paula FJ, Rosen CJ New insights into osteoporosis: the bone-fat connection. J Intern Med 2012; 272(4): 317–329.

9. Gilbert MP, Pratley RE. The impact of diabetes and diabetes medications on bone health. Endocr Rev 2015; 36(2): 194–213.

10. Maurer MS, Burcham J, Cheng H. Diabetes mellitus is associated with an increased risk of falls in elderly residents of a long-term care facility. J Gerontol A Biol Sci Med Sci 2005; 60(9): 1157–1162.

11. Yamamoto M. Insights into bone fragility in diabetes: the crucial role of bone quality on skeletal strength. Endocr J 2015; 62(4): 299–308.

12. Bolland MJ, Grey A, Gamble GD et al. Vitamin D supplementation and falls: a trial sequential meta-analysis. Lancet Diabetes Endocrinol 2014; 2(7): 573–580.

13. Burghardt AJ, Issever AS, Schwartz AV et al. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95(11): 5045–5555.

14. Neumann E, Junker S, Schett G et al. Adipokines in bone disease. Nat Rev Rheumatol 2016; 12(5): 296–302.

15. Montagnani A, Gonnelli S, Alessandri M et al. Osteoporosis and risk of fracture in patients with diabetes: an update. Aging Clin Exp Res 2011; 23(2): 84–90.

16. Maalouf NM. Impact of Anti-hyperglycemic Medications on Bone Health. Clinic Rev Bone Miner Metab 2015; 13(1): 43–52.

17. Lecka-Czernik B. Safety of Antidiabetic Therapies on Bone. Clinic Rev Bone Miner Metab 2013; 11(1): 49–58.

18. Gray A. Diabetes Medications and Bone. Curr Osteoporos Rep 2015; 13(1): 35–40.

19. Mannucci E, Dicembrini I. Drugs for type 2 diabetes: role in the regulation of bone metabolism. Clin Cases Miner Bone Metab 2015; 12(2): 130–134.

20. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38(1): 140–149.

21. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180(1): 32–39.

22. Toulis KA, Goulis DG, Anastasilakis AD. Thiazolidinedione use and the risk of fractures. CMAJ 2009; 180(8): 841–842.

23. Zhu ZN, Jiang YF, Ding T. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone 2014; 68: 115–123. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2014.08.010>.

24. Dormuth CR, Carney G, Carleton B et al. Thiazolidinediones and fractures in men and women. Arch Intern Med 2009; 169(15): 1395–1402.

25. Habib ZA, Havstad SL, Wells K et al. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95(2): 592–600.

26. Ceccarelli E, Guarino EG, Merlotti D et al. Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism. Front Endocrinol (Lausanne) 2013; 4: 73. Dostupné z DOI: <http://dx.doi.org/10.3389/fendo.2013.00073>.

27. Hegazy SK. Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women. J Bone Miner Metab 2015; 33(2): 207–212.

28. Bunck MC, Poelma M, Eekhoff EM et al. Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients. J Diabetes 2012; 4(2): 181–185.

29. Monami M, Dicembrini I, Antenore A et al. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care 2011; 34(11): 2474–2476. Erratum in: Diabetes Care 2014; 37(1): 312.

30. Driessen JH, van Onzenoort HA, Henry RM et al. Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture. Bone 2014; 68: 124–130. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2014.07.030>.

31. Scirica BM, Bhatt DL, Braunwald E et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369(14): 1317–1326.

32. Bunck MC, Eliasson B, Cornér A et al. Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13(4): 374–377.

33. Gilbert MP, Marre M, Holst JJ et al. Comparison of the long-term effects of liraglutide and glimepiride monotherapy on bone mineral density in patients with type 2 diabetes. Endocr Pract 2016; 22(4): 406–411.

34. Mabilleau G, Mieczkowska A, Chappard D. Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials. J Diabetes 2014; 6(3): 260–266.

35. Driessen JH, Henry RM, van Onzenoort HA et al. Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis. Calcif Tissue Int 2015; 97(2): 104–112.

36. Su B, Sheng H, Zhang M et al. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials. Endocrine 2015; 48(1): 107–115.

37. Pfeffer MA, Claggett B, Diaz R et al. [ELIXA Investigators]. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015; 373(23): 2247–2257.

38. Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol 2015; 3(1): 8–10.

39. Mabilleau G, Chappard D, Flatt PR et al. Effects of anti-diabetic drugs on bone metabolism. Expert Rev Endocrinol Metab 2015; 10(6): 663–675.

40. Canagliflozin: Clinical Efficacy and Safety Endocrinologic and Metabolic Drugs Advisory Committee Meeting January 10, 2013. Dostupné z WWW: <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM336234.pdf>.

41. Bode B, Stenlöf K, Harris S et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes. Diabetes Obes Metab 2015; 17(3): 294–303.

42. Kohan DE, Fioretto P, Tang W et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014; 85(4): 962–971.

43. FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. Dostupné z WWW: <http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm>.

44. Zinman B, Wanner C, Lachin JM et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117–2128.

45. Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet 2014; 53(3): 213–225.